keyword
MENU ▼
Read by QxMD icon Read
search

Nivolumab lung

keyword
https://www.readbyqxmd.com/read/29352490/oral-lichenoid-reaction-showing-multiple-ulcers-associated-with-anti-programmed-death-cell-receptor-1-treatment-a-report-of-two-cases-and-published-work-review
#1
Koya Obara, Mamiko Masuzawa, Yasuyuki Amoh
Anti-programmed cell death receptor-1 (PD-1) antibodies represent an effective treatment opinion for advanced melanoma and non-small-cell lung cancer, as well as other cancerous entities. Immune checkpoint inhibitors such as anti-PD-1 antibody result in a unique side-effect profile, commonly described as immune-related adverse events (irAE). These irAE affect the skin, gastrointestinal tract, liver, endocrine system and other organ systems. We report two cases of oral lichenoid reaction showing multiple ulcers associated with nivolumab treatment...
January 20, 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29344020/a-case-of-immune-thrombocytopenia-as-a-rare-side-effect-of-an-immunotherapy-with-pd1-blocking-agents-for-metastatic-melanoma
#2
Claudia Pföhler, Hermann Eichler, Barbara Burgard, Nathalie Krecké, Cornelia S L Müller, Thomas Vogt
Background: Checkpoint blocking agents such as pembrolizumab or nivolumab may induce a diversity of mostly autoimmune-mediated side effects. These autoimmune phenomena mainly affect ductless glands such as the pituitary gland (hypophysitis), the thyroid gland (thyreoiditis), the skin (vitiligo and rash), the colon (colitis), and the lung (pneumonitis). Furthermore, many other organs or organ systems may be affected. Case Report: This work describes a case of an immune thrombocytopenia that developed or rather became clinically significant shortly after initiation of a systemic therapy with first nivolumab and later pembrolizumab given due to metastatic melanoma...
November 2017: Transfusion Medicine and Hemotherapy
https://www.readbyqxmd.com/read/29336998/developing-a-predictive-model-for-clinical-outcomes-of-advanced-non-small-cell-lung-cancer-patients-treated-with-nivolumab
#3
Wungki Park, Deukwoo Kwon, Diana Saravia, Amrita Desai, Fernando Vargas, Mohamed El Dinali, Jessica Warsch, Roy Elias, Young Kwang Chae, Dae Won Kim, Sean Warsch, Adrian Ishkanian, Chukwuemeka Ikpeazu, Raja Mudad, Gilberto Lopes, Mohammad Jahanzeb
INTRODUCTION: Despite significant improvement of clinical outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immunotherapy, our knowledge of optimal biomarkers is still limited. PATIENTS AND METHODS: We retrospectively evaluated 159 advanced NSCLC patients in our institution treated with nivolumab after disease progression during platinum-based chemotherapy. We correlated several variables with progression-free survival (PFS) to develop the immunotherapy, Sex, Eastern Cooperative Oncology Group performance status, Neutrophil-to-lymphocyte ratio (NLR), and Delta NLR (iSEND) model...
December 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29333023/nivolumab-pearls-of-evidence
#4
REVIEW
Pratishtha B Chaudhari
Purpose: Nivolumab is one of the most extensively studied immune checkpoint inhibitors across various tumor types. In this narrative review, the current clinical efficacy and safety data of anti-programmed death-1 (PD-1) nivolumab for nonsmall cell lung cancer (NSCLC) and renal cell cancer (RCC) are elucidated. Methods: Systematic search was done on Pubmed, Medline, Embase, Web of Knowledge, and Cochrane Central through September 2016 for controlled prospective interventional studies of nivolumab across two indications - NSCLC and RCC...
October 2017: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/29327061/egfr-tki-associated-interstitial-pneumonitis-in-nivolumab-treated-patients-with-non-small-cell-lung-cancer
#5
Yasuo Oshima, Tetsuya Tanimoto, Koichiro Yuji, Arinobu Tojo
Importance: Nivolumab and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are now the standard-of-care therapies in non-small cell lung cancer (NSCLC). Although EGFR-TKIs are well understood and have well-defined safety profiles, our experience with immune checkpoint inhibitors is still growing, particularly regarding the use of combinations of different classes of antitumor agents, including both the concomitant and sequential use of such agents. Objective: To determine whether nivolumab increases EGFR-TKI-associated interstitial pneumonitis (IP)...
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29321933/acute-progression-of-aspergillosis-in-a-patient-with-lung-cancer-receiving-nivolumab
#6
Naohiro Uchida, Kohei Fujita, Koichi Nakatani, Tadashi Mio
A 65-year-old man with chronic progressive pulmonary aspergillosis (CPPA) was admitted for the treatment of lung adenocarcinoma while receiving an immune checkpoint inhibitor, nivolumab. The tumour responded well to the therapy, but the cavity of CPPA became large in contrast to the tumour after 20 courses of therapy. He was diagnosed as having exacerbation of CPPA and successfully and concurrently treated with an antifungal agent and nivolumab. Since there was absence of obvious immunosuppression and the presence of a drastic effect on tumour remission during nivolumab therapy, this phenomenon suggested that the trigger of CPPA progression was dependent not on immunosuppression but on a hyperreaction to microorganisms, which was similar to the immune reconstitution inflammatory syndrome caused by nivolumab...
February 2018: Respirology Case Reports
https://www.readbyqxmd.com/read/29317551/characteristics-of-real-world-metastatic-non-small-cell-lung-cancer-patients-treated-with-nivolumab-and-pembrolizumab-during-the-year-following-approval
#7
Sean Khozin, Amy P Abernethy, Nathan C Nussbaum, Jizu Zhi, Melissa D Curtis, Melisa Tucker, Shannon E Lee, David E Light, Anala Gossai, Rachael A Sorg, Aracelis Z Torres, Payal Patel, Gideon Michael Blumenthal, Richard Pazdur
BACKGROUND: Evidence from cancer clinical trials can be difficult to generalize to real-world patient populations, but can be complemented by real-world evidence to optimize personalization of care. Further, real-world usage patterns of programmed cell death protein 1 (PD-1) inhibitors following approval can inform future studies of subpopulations underrepresented in clinical trials. MATERIALS AND METHODS: We performed a multicenter analysis using electronic health record data collected during routine care of patients treated in community cancer care clinics in the Flatiron Health network...
January 9, 2018: Oncologist
https://www.readbyqxmd.com/read/29314333/programmed-cell-death-1-blockade-induced-cutaneous-sarcoid-like-epithelioid-granulomas-in-advanced-melanoma-a-case-report
#8
T Ogawa, Y Ishitsuka, K Iwamoto, H Koguchi-Yoshioka, R Tanaka, R Watanabe, Y Fujisawa, M Fujimoto
Sarcoidosis is a chronic, systemic inflammatory disorder of unknown etiology that is characterized by the formation of noncaseating granuloma in affected organs, most commonly the lung.1 In pulmonary sarcoidosis patients, the T helper 1 (Th1) cytokine profile of CD4+ as well as CD8+ T cells was demonstrated in bronchoalveolar lavage fluid.2 However, there has been no detailed description of a lymphocyte profile in cutaneous sarcoid-like epithelioid granulomas. Here, we report a case of sarcoid-like epithelioid granulomas induced by nivolumab in a patient with advanced melanoma and we performed functional lymphocyte analysis of the granuloma lesions...
January 5, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29303787/supportive-care-in-the-era-of-immunotherapies-for-advanced-non-small-cell-lung-cancer
#9
Gil Awada, Jean Klastersky
PURPOSE OF REVIEW: The therapeutic armamentarium for advanced non-small-cell lung cancer has evolved considerably over the past years. Immune checkpoint inhibitors targeting programmed cell death-1 such as pembrolizumab and nivolumab or programmed cell death ligand 1 such as atezolizumab, durvalumab and avelumab have shown favorable efficacy results in this patient population in the first-line and second-line setting. These immunotherapies are associated with a distinct toxicity profile based on autoimmune organ toxicity which is a new challenge for supportive care during treatment with these drugs...
January 4, 2018: Current Opinion in Oncology
https://www.readbyqxmd.com/read/29299404/evaluation-of-rare-but-severe-immune-related-adverse-effects-in-pd-1-and-pd-l1-inhibitors-in-non-small-cell-lung-cancer-a-meta-analysis
#10
Yang-Bo Hu, Qun Zhang, Hui-Juan Li, Jean Maire Michot, Hong-Bing Liu, Ping Zhan, Tang-Feng Lv, Yong Song
Background: Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitor therapy is showing marked efficacy in advanced non-small cell lung cancer (NSCLC). Meanwhile, it is concomitant with distinctive immune-related adverse effects. We aim to describe the incidence of pneumonitis and other rare but severe immune-related adverse effects (IRAEs), as well as treatment related deaths. In addition, we analyze the differences in incidence of pneumonitis between PD-1 and PD-L1 inhibitors and standard-of-care chemotherapy...
December 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29290267/comparative-effectiveness-of-immune-checkpoint-inhibitors-for-previously-treated-advanced-non-small-cell-lung-cancer-a-systematic-review-and-network-meta-analysis-of-3024-participants
#11
Pui San Tan, Pedro Aguiar, Benjamin Haaland, Gilberto Lopes
INTRODUCTION: Role of PD-L1 expression to guide immunotherapies in previously treated advanced NSCLC remains unclear and there is a lack of data comparing immune checkpoint inhibitors (ICIs) with each other. This network meta-analysis (NMA) aims to compare survival with ICIs to docetaxel and perform indirect comparisons between ICIs in the PD-L1 unselected population and by PD-L1 expression levels. METHODS: PubMed was searched and study screening was performed by two independent reviewers...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290265/correlation-between-immune-related-adverse-events-and-efficacy-in-non-small-cell-lung-cancer-treated-with-nivolumab
#12
Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Seigo Sasaki, Kuninobu Kanai, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto
OBJECTIVES: Patients treated with nivolumab often experience its unique adverse events, called immune-related adverse events (irAEs). Regarding the mechanisms of immune-checkpoint inhibitors (ICIs), the occurrence of irAEs may also reflect antitumor responses. Here, we report the clinical correlation between irAEs and efficacy in NSCLC patients treated with nivolumab. MATERIALS AND METHODS: Between December 2015 and February 2017, 38 advanced NSCLC patients were treated in our institution...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29290261/does-nivolumab-for-progressed-metastatic-lung-cancer-fulfill-its-promises-an-efficacy-and-safety-analysis-in-20-general-hospitals
#13
Kurt G Tournoy, Michiel Thomeer, Paul Germonpré, Sofie Derijcke, Rebecca De Pauw, Daniëlla Galdermans, Karl Govaert, Elke Govaerts, Rob Schildermans, Isabelle Declercq, Nele De Brucker, Karin Pat, Rika Van Herreweghe, Luc Van Zandweghe, Luc Vanmaele, Valerie Van Damme, Heidi Marien, Sofie De Craene, Isabelle Fabry, Patrick Alexander, Piet Vercauter, Ingel Demedts
OBJECTIVES: In patients with refractory or recurrent non-small-cell lung cancer (NSCLC) after first line chemotherapy, phase III trials showed superiority of nivolumab, an IgG4 programmed death-1 immune-checkpoint-inhibitor antibody, over docetaxel. We evaluated case mix, effectiveness and safety of nivolumab upon implementation in general practice. MATERIALS AND METHODS: In 20 general hospitals, all consecutive NSCLC patients treated with nivolumab within the medical need program (inclusion period 12 months) in Flanders - Belgium were evaluated...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29285361/response-to-nivolumab-in-metastatic-collecting-duct-carcinoma-expressing-pd-l1-a-case-report
#14
Kosuke Mizutani, Kengo Horie, Shingo Nagai, Tomohiro Tsuchiya, Chiemi Saigo, Kazuhiro Kobayashi, Tatsuhiko Miyazaki, Takashi Deguchi
The authors present a case report of collecting duct carcinoma (CDC) that responded to nivolumab, a programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, following the failure of systemic treatment with chemotherapy and targeted therapy. The patient underwent right radical nephrectomy and segmentectomy of the lung following chemotherapy. Fifteen months following the first surgery, segmentectomy and subsequent second-line chemotherapy were performed for recurrence in the lung. Targeted therapy with temsirolimus for recurrence of the lung and lymph node metastases was ultimately used for 30 months...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29279511/a-case-of-iga-nephropathy-after-nivolumab-therapy-for-postoperative-recurrence-of-lung-squamous-cell-carcinoma
#15
Seiji Kishi, Masanori Minato, Atsuro Saijo, Naoka Murakami, Masanori Tamaki, Motokazu Matsuura, Taichi Murakami, Kojiro Nagai, Hideharu Abe, Yasuhiko Nishioka, Toshio Doi
Immune checkpoint inhibitors (ICIs) are becoming a common and important cancer therapy. ICIs are associated with a unique category of side effects, termed immune-related adverse events (irAEs). We herein report the case of a 72-year-old man with postoperative recurrence of lung squamous cell carcinoma who was treated with nivolumab and who developed proteinuria and a worsening kidney function. A kidney biopsy revealed IgA nephropathy. After drug withdrawal, the proteinuria improved and the deterioration of the patient's renal function was halted...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29279482/immune-related-colitis-induced-by-the-long-term-use-of-nivolumab-in-a-patient-with-non-small-cell-lung-cancer
#16
Yuichiro Yasuda, Yoshiko Urata, Rie Tohnai, Shoichi Ito, Yoshitaka Kawa, Yuko Kono, Yoshihiro Hattori, Masahiro Tsuda, Toshiko Sakuma, Shunichi Negoro, Miyako Satouchi
We herein report a case of immune-related colitis induced by the long-term use of nivolumab. A 62-year-old Japanese man was treated with nivolumab at 3 mg/kg every 2 weeks for advanced lung adenocarcinoma. The patient was admitted to our hospital due to non-bloody watery diarrhea after the 70th dose of nivolumab. A biopsy specimen of the colon mucosa revealed evidence of colitis with cryptitis and crypt microabscesses. He was diagnosed with immune-related colitis and started on predonisolone 60 mg/day. Subsequently, his symptoms remarkably resolved...
December 27, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29277824/carcinoembryonic-antigen-as-a-predictive-biomarker-of-response-to-nivolumab-in-non-small-cell-lung-cancer
#17
Yuki Kataoka, Katsuya Hirano, Tomoko Narabayashi, Satoshi Hara, Daichi Fujimoto, Tae Tanaka, Noriyuki Ebi, Keisuke Tomii, Hiroshige Yoshioka
AIM: To find new predictive factors for the efficient use of immune checkpoint inhibitors in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: In this multicenter retrospective cohort study, we evaluated consecutive patients treated with nivolumab between January and October 2016 after second-line systemic chemotherapy. The endpoint was progression-free survival (PFS), as defined by Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: A total of 189 patients were included in the study...
January 2018: Anticancer Research
https://www.readbyqxmd.com/read/29261621/dynamic-adaptation-of-tumor-immune-response-with-nivolumab-demonstrated-by-18f-fdg-pet-ct
#18
Naghmehossadat Eshghi, Tamara F Lundeen, Phillip H Kuo
A 61-year-old woman with lung adenocarcinoma failed first-line treatment and was placed on immunotherapy with nivolumab. FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton. Seven weeks after starting nivolumab, FDG-PET/CT showed mild residual activity in thoracic nodes and otherwise complete response. After 15 weeks, enlarged and FDG-avid axillary lymphadenopathy and worsening supraclavicular lymphadenopathy developed. After 20 weeks, FDG-PET/CT demonstrated marked improvement of axillary and supraclavicular lymphadenopathy...
December 19, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29260625/immune-mediated-thrombocytopenia-and-hypothyroidism-in-a-lung-cancer-patient-treated-with-nivolumab
#19
Takanobu Jotatsu, Keishi Oda, Yudai Yamaguchi, Shingo Noguchi, Toshinori Kawanami, Takashi Kido, Minoru Satoh, Kazuhiro Yatera
Patients treated with immune checkpoint inhibitors can develop various immunological complications; however, few cases of immune thrombocytopenia occurring in association with the administration of these agents have so far been reported. We herein report the case of a 62-year-old Japanese man with non-small-cell lung cancer who developed immune thrombocytopenia and hypothyroidism during nivolumab therapy. After the second administration of the drug, his peripheral blood platelet count rapidly decreased to 1...
February 2018: Immunotherapy
https://www.readbyqxmd.com/read/29249765/acute-cerebellar-ataxia-induced-by-nivolumab
#20
Reina Kawamura, Eiichiro Nagata, Masako Mukai, Yoichi Ohnuki, Tomohiko Matsuzaki, Kana Ohiwa, Tomoki Nakagawa, Mitsutomo Kohno, Ryota Masuda, Masayuki Iwazaki, Shunya Takizawa
A 54-year-old woman with adenocarcinoma of the lung and lymph node metastasis experienced nystagmus and cerebellar ataxia 2 weeks after initiating nivolumab therapy. An evaluation for several autoimmune-related antibodies and paraneoplastic syndrome yielded negative results. We eventually diagnosed the patient with nivolumab-induced acute cerebellar ataxia, after excluding other potential conditions. Her ataxic gait and nystagmus resolved shortly after intravenous steroid pulse therapy followed by the administration of decreasing doses of oral steroids...
2017: Internal Medicine
keyword
keyword
107280
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"